Last reviewed · How we verify
Dose D2 of Interleukin-2
Interleukin-2 activates and expands T cells and natural killer cells to enhance anti-tumor immune responses.
Interleukin-2 activates and expands T cells and natural killer cells to enhance anti-tumor immune responses. Used for Advanced or metastatic cancer (specific indication under investigation in Phase 2).
At a glance
| Generic name | Dose D2 of Interleukin-2 |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Cytokine immunotherapy |
| Target | IL-2 receptor (CD25, CD122, CD132) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
IL-2 is a cytokine that binds to IL-2 receptors on lymphocytes, promoting their proliferation, differentiation, and activation. This leads to enhanced cytotoxic T cell and NK cell activity against cancer cells. Dose D2 refers to a specific dosing regimen in this Phase 2 trial.
Approved indications
- Advanced or metastatic cancer (specific indication under investigation in Phase 2)
Common side effects
- Fever
- Chills
- Fatigue
- Nausea
- Vomiting
- Hypotension
- Capillary leak syndrome
- Thrombocytopenia
Key clinical trials
- Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes (PHASE2)
- MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dose D2 of Interleukin-2 CI brief — competitive landscape report
- Dose D2 of Interleukin-2 updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI